Enveric Biosciences, Inc. (ENVB): Nasdaq/NYSE listing notice — Enveric Biosciences receives Nasdaq delisting notice for bid price below $1.00

Enveric Biosciences, Inc.

Closing bid price below $1.00 for 30 consecutive business days as of May 16, 2024.
Company has 180 days, until November 12, 2024, to regain compliance by closing at or above $1.00 for 10 consecutive days.
If not compliant by deadline, may be eligible for additional 180 days if other listing standards met.
Company considering available options, including potential reverse stock split, to cure deficiency.
Failure to regain compliance could result in delisting from Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 16, 2024, Enveric Biosciences, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notificat

View on SEC.gov

99 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-020489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.